title: Albusin B, mass-produced by the Saccharomyces cerevisiae suppression system, enhances lipid utilisation and antioxidant capacity in mice.
abstract: BACKGROUND
  Albusin B (bacteriocin), isolated from Ruminococcus albus 7 and mass-produced by the Saccharomyces cerevisiae expression system, has previously been shown to have a beneficial effect on lipid metabolism in broiler chickens. The present study was focused on the effect of albusin B on lipid metabolism in mice and the potential of albusin B-expressing yeast product (albusin B) as a food supplement. Forty-five BALB/c male mice at 6 weeks of age were each orally administered normal saline (control), yeast (0.125 mg kg(-1) ) or albusin B (0.125 mg kg(-1) ) for 14 days and then euthanised.
  
  
  RESULTS
  Compared with the control group, albusin B-fed mice exhibited decreased body weight and plasma levels of triglycerides and free fatty acids but increased plasma high-density lipoprotein. Albusin B-fed mice showed higher mRNA expression of fatty acid oxidation in the ileum, heart and liver than control mice. Compared with the control treatment, both yeast and albusin B treatments caused a decrease in mRNA expression of fatty acid synthesis in the heart and liver. Moreover, albusin B suppressed mRNA levels of lipogenesis in the ileum and liver. Albusin B-fed mice exhibited more favourable adenosine triphosphate production and antioxidant capacity in the heart and liver. Albusin B treatment led to a significantly lower respiratory quotient than that of the control, whereas yeast treatment did not.
  
  
  CONCLUSIONS
  This study demonstrated a beneficial effect of albusin B on lipid utilisation and anti-atherosclerotic and antioxidant capacities in mice. However, more comprehensive studies are required to elucidate the exact mechanism behind the effect of albusin B.
authors.affiliation: Department of Animal Science and Technology, National Taiwan University, No. 50, Lane 155, Sec. 3, Keelung Rd, Taipei, Taiwan.
authors.forename: Ya-Hui
authors.initials: YH
authors.lastname: Hsieh
authors.forename: Han-Tsung
authors.initials: HT
authors.lastname: Wang
authors.forename: Jih-Tay
authors.initials: JT
authors.lastname: Hsu
authors.forename: Ching-Yi
authors.initials: CY
authors.lastname: Chen
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000975:Antioxidants / Q000378:metabolism*; D001430:Bacteriocins / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D001481:Basal Metabolism; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011897:Random Allocation; D012441:Saccharomyces cerevisiae
chemical_list: D000975:Antioxidants; D001430:Bacteriocins; C581354:albusin B, Ruminococcus albus
keywords: albusin B; anti-atherosclerosis; antioxidant capacity; lipid utilisation; mice